

# Kohei Shitara

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/94047/publications.pdf>

Version: 2024-02-01

197  
papers

15,046  
citations

50276

46  
h-index

22832

112  
g-index

215  
all docs

215  
docs citations

215  
times ranked

12294  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer. <i>JAMA Oncology</i> , 2018, 4, e180013.	7.1	1,350
2	First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. <i>Lancet</i> , The, 2021, 398, 27-40.	13.7	1,237
3	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. <i>Lancet</i> , The, 2018, 392, 123-133.	13.7	984
4	Regulatory T cells in cancer immunosuppression – implications for anticancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 356-371.	27.6	872
5	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 2419-2430.	27.0	681
6	PD-1 <sup>+</sup> regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9999-10008.	7.1	655
7	Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer. <i>JAMA Oncology</i> , 2020, 6, 1571.	7.1	611
8	Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). <i>Journal of Clinical Oncology</i> , 2020, 38, 2053-2061.	1.6	469
9	The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. <i>Nature Immunology</i> , 2020, 21, 1346-1358.	14.5	431
10	Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. <i>Lancet Oncology</i> , The, 2017, 18, 640-653.	10.7	383
11	Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1437-1448.	10.7	345
12	The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. <i>Nature</i> , 2021, 600, 727-730.	27.8	335
13	Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. <i>Lancet Oncology</i> , The, 2017, 18, 1512-1522.	10.7	317
14	Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 234-247.	10.7	268
15	Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. <i>Cancer Cell</i> , 2022, 40, 201-218.e9.	16.8	266
16	Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 420-435.	10.7	191
17	Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. <i>Gastric Cancer</i> , 2017, 20, 407-415.	5.3	189
18	Regulatory T cells: a potential target in cancer immunotherapy. <i>Annals of the New York Academy of Sciences</i> , 2018, 1417, 104-115.	3.8	184

#	ARTICLE	IF	CITATIONS
19	Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instabilityâ€“High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. <i>JAMA Oncology</i> , 2021, 7, 895.	7.1	184
20	Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1057-1065.	10.7	160
21	Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. <i>Nature</i> , 2022, 603, 942-948.	27.8	156
22	Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. <i>Lancet Oncology</i> , The, 2019, 20, 827-836.	10.7	154
23	Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 277-287.	8.1	141
24	Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 473-487.	27.6	139
25	Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment. , 2018, 6, 106.		138
26	Disease-Free Survival as a Surrogate for Overall Survival in Adjuvant Trials of Gastric Cancer: A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1600-1607.	6.3	133
27	KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. <i>Future Oncology</i> , 2019, 15, 943-952.	2.4	133
28	Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 793-802.	5.3	124
29	An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells. <i>Immunity</i> , 2020, 53, 187-203.e8.	14.3	119
30	Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, LBA4007-LBA4007.	1.6	119
31	Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 1098-1107.	1.6	118
32	First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. <i>Future Oncology</i> , 2021, 17, 491-501.	2.4	117
33	TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study. <i>Lancet Oncology</i> , The, 2017, 18, 1172-1181.	10.7	111
34	Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients. <i>Gastric Cancer</i> , 2016, 19, 183-191.	5.3	95
35	Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 501-510.	8.1	88
36	Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205). <i>Gastric Cancer</i> , 2017, 20, 341-349.	5.3	79

#	ARTICLE	IF	CITATIONS
37	Progression-Free Survival as a Surrogate for Overall Survival in Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1667-1670.	6.3	78
38	Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy. <i>Gastric Cancer</i> , 2017, 20, 175-181.	5.3	77
39	<i>ABO</i> Genotype and the Risk of Gastric Cancer, Atrophic Gastritis, and <i>Helicobacter pylori</i> Infection. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1665-1672.	2.5	76
40	Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4013-4013.	1.6	75
41	Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 301-307.	2.3	71
42	The New Era of Immunotherapy in Gastric Cancer. <i>Cancers</i> , 2022, 14, 1054.	3.7	68
43	Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment. <i>Gastric Cancer</i> , 2013, 16, 261-267.	5.3	67
44	Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 927-938.	5.3	67
45	A Low Tumor Mutational Burden and <i>PTEN</i> Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 3714-3724.	7.0	61
46	Randomized study of <sc>FOLFIRI</sc> plus either panitumumab or bevacizumab for wild-type <sc>KRAS</sc> colorectal cancerâ€“<sc>WJOG</sc> 6210G. <i>Cancer Science</i> , 2016, 107, 1843-1850.	3.9	60
47	Association of prostate stem cell antigen gene polymorphisms with the risk of stomach cancer in Japanese. <i>International Journal of Cancer</i> , 2009, 125, 1961-1964.	5.1	59
48	Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score $\geq 10$ . <i>Clinical Cancer Research</i> , 2021, 27, 1923-1931.	7.0	53
49	Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study. <i>British Journal of Cancer</i> , 2017, 117, 1450-1458.	6.4	52
50	First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 531-540.	4.1	49
51	The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3784-3790.	7.0	49
52	Heavy smoking history interacts with chemoradiotherapy for esophageal cancer prognosis: A retrospective study. <i>Cancer Science</i> , 2010, 101, 1001-1006.	3.9	46
53	Dramatic Tumor Response to Everolimus for Malignant Epithelioid Angiomyolipoma. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 814-816.	1.3	45
54	Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epsteinâ€“Barr virus status, and cancer genome alterations in metastatic gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 69-76.	5.3	45

#	ARTICLE	IF	CITATIONS
55	Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial. <i>Gastric Cancer</i> , 2019, 22, 155-163.	5.3	44
56	Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. <i>Anticancer Research</i> , 2011, 31, 3535-41.	1.1	44
57	Current status of immunotherapy for advanced gastric cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 20-27.	1.3	43
58	Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407). <i>Gastric Cancer</i> , 2017, 20, 1004-1009.	5.3	42
59	HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer. <i>World Journal of Clinical Cases</i> , 2019, 7, 1964-1977.	0.8	39
60	A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study). <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 1082-1086.	1.3	38
61	Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition) Tj ETQq1 1,0,784314,rgBT /Ome	3.9	38
62	The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4537-4537.	1.6	38
63	Folate Intake along with Genetic Polymorphisms in Methylenetetrahydrofolate Reductase and Thymidylate Synthase in Patients with Advanced Gastric Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1311-1319.	2.5	35
64	Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study. <i>Clinical Cancer Research</i> , 2022, 28, 3489-3498.	7.0	35
65	Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG. <i>Gastric Cancer</i> , 2017, 20, 904-912.	5.3	33
66	Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy. <i>Annals of Surgical Oncology</i> , 2019, 26, 465-472.	1.5	32
67	A randomized controlled trial comparing primary tumour resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: JCOG1007 (iPACS study). <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 89-93.	1.3	30
68	Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti-PD-1 Therapy. <i>Clinical Cancer Research</i> , 2022, 28, 2110-2117.	7.0	30
69	Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials. <i>Investigational New Drugs</i> , 2012, 30, 1224-1231.	2.6	29
70	Bevacizumab Chemotherapy for Pulmonary Epithelioid Hemangioendothelioma with Severe Dyspnea. <i>Journal of Thoracic Oncology</i> , 2011, 6, 651-652.	1.1	27
71	Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors. <i>Anti-Cancer Drugs</i> , 2015, 26, 1043-1053.	1.4	27
72	Circulating Tumor DNA Analysis Detects <i>FGFR2</i> Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5619-5627.	7.0	27

#	ARTICLE	IF	CITATIONS
73	The association of molecular biomarkers with efficacy of pembrolizumab versus paclitaxel in patients with gastric cancer (GC) from KEYNOTE-061.. Journal of Clinical Oncology, 2020, 38, 4512-4512.	1.6	26
74	Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer. Gastric Cancer, 2014, 17, 362-370.	5.3	25
75	NC-6004 Phase I study in combination with gemcitabine for advanced solid tumors and population PK/PD analysis. Cancer Chemotherapy and Pharmacology, 2017, 79, 569-578.	2.3	25
76	Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia. JAMA Network Open, 2019, 2, e198243.	5.9	25
77	Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G). Gastric Cancer, 2020, 23, 677-688.	5.3	25
78	Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2020, 85, 855-862.	2.3	24
79	Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer. Gastric Cancer, 2021, 24, 780-789.	5.3	24
80	Reporting patient characteristics and stratification factors in randomized trials of systemic chemotherapy for advanced gastric cancer. Gastric Cancer, 2012, 15, 137-143.	5.3	23
81	Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors. Japanese Journal of Clinical Oncology, 2020, 50, 859-866.	1.3	23
82	Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer. ESMO Open, 2020, 5, e000775.	4.5	22
83	Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with <i>MET</i>-amplified gastric cancer. Oncotarget, 2017, 8, 79546-79555.	1.8	21
84	Association between insulin-like growth factor-1 polymorphisms and stomach cancer risk in a Japanese population. Cancer Science, 2011, 102, 2231-2235.	3.9	20
85	Pulmonary metastasectomy for gastric cancer: a 13-year single-institution experience. Surgery Today, 2013, 43, 1382-1389.	1.5	20
86	Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution. Clinical Colorectal Cancer, 2016, 15, e109-e115.	2.3	20
87	Phase I Study of the Focal Adhesion Kinase Inhibitor BI-853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors. Targeted Oncology, 2019, 14, 57-65.	3.6	20
88	Development of circulating tumour DNA analysis for gastrointestinal cancers. ESMO Open, 2020, 5, e000600.	4.5	20
89	Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancer. Gastric Cancer, 2020, 23, 893-903.	5.3	20
90	Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial. The Lancet Gastroenterology and Hepatology, 2021, 6, 209-217.	8.1	20

#	ARTICLE	IF	CITATIONS
91	Combination chemotherapy with S-1 plus cisplatin for gastric cancer that recurs after adjuvant chemotherapy with S-1: multi-institutional retrospective analysis. <i>Gastric Cancer</i> , 2012, 15, 245-251.	5.3	19
92	Serum Concentration of Fentanyl During Conversion From Intravenous to Transdermal Administration to Patients With Chronic Cancer Pain. <i>Clinical Journal of Pain</i> , 2013, 29, 487-491.	1.9	19
93	Advances in Systemic Therapy for Metastatic or Advanced Gastric Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1313-1320.	4.9	19
94	A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer. <i>Gastric Cancer</i> , 2022, 25, 619-628.	5.3	18
95	Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2011, 14, 155-160.	5.3	17
96	KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJC): A double-blind, randomized, placebo-controlled phase 3 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS4146-TPS4146.	1.6	17
97	Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. <i>Investigational New Drugs</i> , 2012, 30, 787-793.	2.6	16
98	Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1383-1389.	2.5	16
99	Chemotherapy for advanced gastric cancer: future perspective in Japan. <i>Gastric Cancer</i> , 2017, 20, 102-110.	5.3	16
100	First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2019, 37, 507-518.	2.6	16
101	Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy. <i>JAMA Oncology</i> , 2020, 6, e193531.	7.1	16
102	Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS. <i>Gastric Cancer</i> , 2020, 23, 689-698.	5.3	16
103	Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592098651.	3.2	16
104	Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 811-824.	3.1	16
105	Chemoradiotherapy for treatment of esophageal cancer in Japan: current status and perspectives. <i>Gastrointestinal Cancer Research: GCR</i> , 2009, 3, 66-72.	0.7	16
106	Suspected paclitaxel-induced pneumonitis. <i>Gastric Cancer</i> , 2006, 9, 325-328.	5.3	15
107	Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis. <i>Gastric Cancer</i> , 2013, 16, 48-55.	5.3	15
108	A Phase I Study of Napabucasin Plus Paclitaxel for Japanese Patients With Advanced/Recurrent Gastric Cancer. <i>In Vivo</i> , 2019, 33, 933-937.	1.3	15

#	ARTICLE	IF	CITATIONS
109	Dawn of precision medicine on gastric cancer. <i>International Journal of Clinical Oncology</i> , 2019, 24, 779-788.	2.2	15
110	Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy. <i>Asian Pacific Journal of Cancer Prevention</i> , 2010, 11, 447-52.	1.2	14
111	Chemotherapy for Gastric Cancer that Recurs After Adjuvant Chemotherapy with S-1. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 786-789.	1.3	13
112	Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS ( KRAS/NRAS ) Wild-type, Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017, 16, 158-163.	2.3	13
113	Transient Depletion of CD4+ Cells Induces Remodeling of the TCR Repertoire in Gastrointestinal Cancer. <i>Cancer Immunology Research</i> , 2021, 9, 624-636.	3.4	13
114	The nationwide cancer genome screening project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced gastric cancer (GC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4050-4050.	1.6	13
115	Prognostic factors for metastatic colorectal cancer patients undergoing irinotecan-based second-line chemotherapy. <i>Gastrointestinal Cancer Research: GCR</i> , 2011, 4, 168-72.	0.7	13
116	Phase I study of the irreversible fibroblast growth factor receptor 1 inhibitor futibatinib in Japanese patients with advanced solid tumors. <i>Cancer Science</i> , 2023, 114, 574-585.	3.9	13
117	Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS. <i>Investigational New Drugs</i> , 2011, 29, 688-693.	2.6	12
118	Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017, 16, e39-e44.	2.3	12
119	Dose-finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumors. <i>Cancer Science</i> , 2018, 109, 3216-3223.	3.9	12
120	Efficacy of trastuzumab emtansine in Japanese patients with previously treated HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: A subgroup analysis of the GATSBY study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 5-13.	1.1	12
121	Hepatic Arterial Infusion of Oxaliplatin for a Patient with Hepatic Metastases from Colon Cancer Undergoing Hemodialysis. <i>Japanese Journal of Clinical Oncology</i> , 2007, 37, 540-543.	1.3	11
122	A retrospective comparison of S-1 plus cisplatin and capecitabine plus cisplatin for patients with advanced or recurrent gastric cancer. <i>International Journal of Clinical Oncology</i> , 2013, 18, 539-546.	2.2	11
123	Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study. <i>ESMO Open</i> , 2021, 6, 100200.	4.5	11
124	Feasibility study of cancer genome alterations identified by next generation sequencing: ABC study. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 559-564.	1.3	10
125	Antibody-drug conjugates to treat gastric cancer. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 923-930.	3.1	10
126	A multicenter phase II study of TAS-114 in combination with S-1 in patients with pretreated advanced gastric cancer (EPOC1604). <i>Gastric Cancer</i> , 2021, 24, 190-196.	5.3	10



#	ARTICLE	IF	CITATIONS
127	A phase II study of futibatinib (TAS-120) in patients (pts) with advanced (adv) solid tumors harboring fibroblast growth factor receptor (FGFR) genomic aberrations.. Journal of Clinical Oncology, 2020, 38, TPS470-TPS470.	1.6	10
128	Phase III study of pembrolizumab combined with S-1+oxaliplatin or S-1+cisplatin as first-line chemotherapy for gastric cancer. Cancer Science, 2022, 113, 2814-2827.	3.9	10
129	Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma. ESMO Open, 2018, 3, e000443.	4.5	9
130	Next-generation sequencing and biomarkers for gastric cancer: what is the future?. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591984818.	3.2	9
131	Emergence of Concurrent Multiple EGFR Mutations and MET Amplification in a Patient With EGFR-Amplified Advanced Gastric Cancer Treated With Cetuximab. JCO Precision Oncology, 2020, 4, 1407-1413.	3.0	9
132	Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan. Japanese Journal of Clinical Oncology, 2021, 51, 1383-1390.	1.3	9
133	Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience. Journal of Clinical Oncology, 2022, 40, 2458-2467.	1.6	9
134	A case of heavily pretreated rectal cancer with disseminated intravascular coagulation that improved following reintroduction of FOLFOX plus bevacizumab. International Journal of Clinical Oncology, 2011, 16, 766-769.	2.2	8
135	Clinicopathological features and endoscopic findings of HER2-positive gastric cancer. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 3964-3971.	2.4	8
136	Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer. Gastric Cancer, 2018, 21, 106-113.	5.3	8
137	Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial. International Journal of Clinical Oncology, 2020, 25, 301-311.	2.2	8
138	Drug-exposed cancer-associated fibroblasts facilitate gastric cancer cell progression following chemotherapy. Gastric Cancer, 2021, 24, 810-822.	5.3	8
139	The Right Treatment of the Right Patient: Integrating Genetic Profiling Into Clinical Decision Making in Advanced Gastric Cancer in Asia. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e166-e173.	3.8	8
140	Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS). Gastric Cancer, 2022, 25, 586-597.	5.3	8
141	Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials. Clinical Cancer Research, 2022, 28, 3480-3488.	7.0	8
142	Randomized Phase II Study Comparing Dose Escalated Weekly Paclitaxel vs. Standard Dose Weekly Paclitaxel for Patients with Previously Treated Advanced Gastric Cancer. Japanese Journal of Clinical Oncology, 2011, 41, 287-290.	1.3	7
143	Lapatinib Plus Trastuzumab for a Patient with Heavily Pre-treated Gastric Cancer that Progressed after Trastuzumab. Japanese Journal of Clinical Oncology, 2011, 41, 663-665.	1.3	7
144	Trifluridine/tipiracil for the treatment of metastatic gastric cancer. Expert Review of Gastroenterology and Hepatology, 2020, 14, 65-70.	3.0	7

#	ARTICLE	IF	CITATIONS
145	Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094237.	3.2	7
146	The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434). <i>Investigational New Drugs</i> , 2021, 39, 152-162.	2.6	7
147	Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061. <i>Gastric Cancer</i> , 2021, 24, 1330-1340.	5.3	7
148	Chemotherapy for patients with advanced gastric cancer with performance status 2. <i>Gastrointestinal Cancer Research: GCR</i> , 2009, 3, 220-4.	0.7	7
149	Case Series of Cetuximab Monotherapy for Patients with Pre-treated Colorectal Cancer Complicated with Hyperbilirubinemia due to Severe Liver Metastasis. <i>Japanese Journal of Clinical Oncology</i> , 2010, 40, 275-277.	1.3	6
150	Retrospective analysis of cetuximab monotherapy for patients with irinotecan-intolerant metastatic colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2011, 16, 416-420.	2.2	6
151	Comparison of intratumoral heterogeneity of HER2 expression between primary tumor and multiple organ metastases in gastric cancer: Clinicopathological study of three autopsy cases and one resected case. <i>Pathology International</i> , 2015, 65, 309-317.	1.3	6
152	Phase 1 study of ombrabulin in combination with cisplatin (CDDP) in Japanese patients with advanced solid tumors. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 1000-1007.	1.3	6
153	Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 825-830.	3.1	6
154	Cancer-related FGFR2 overexpression and gene amplification in Japanese patients with gastric cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1523-1533.	1.3	6
155	Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1193-1201.	2.4	6
156	Metastatic Rectal Cancer Responding to Third-line Therapy Employing Bevacizumab After Failure of Oxaliplatin and Irinotecan: Case Report. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 493-496.	1.3	5
157	Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 595-603.	2.5	5
158	Ramucirumab for gastric cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 133-139.	3.0	5
159	Human epidermal growth factor receptor 2-, epidermal growth factor receptor-, and mesenchymal epithelial transition factor-positive sites of gastric cancer using surgical samples. <i>Gastric Cancer</i> , 2019, 22, 335-343.	5.3	5
160	Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study. <i>Gastric Cancer</i> , 2021, 24, 970-977.	5.3	5
161	A case of suspected S-1 induced interstitial pneumonia. <i>Japanese Journal of Cancer and Chemotherapy</i> , 2007, 34, 619-22.	0.2	5
162	Retrospective analysis of stage IV advanced gastric cancer treated with S-1 or other chemotherapy. <i>International Journal of Clinical Oncology</i> , 2006, 11, 367-374.	2.2	4

#	ARTICLE	IF	CITATIONS
163	Phase I Study of Docetaxel, Cisplatin and S-1 in Patients with Advanced Gastric Cancer. Japanese Journal of Clinical Oncology, 2010, 40, 1014-1020.	1.3	4
164	Cetuximab plus FOLFOX for Patients with Metastatic Colorectal Cancer with Poor Performance Status and/or Severe Tumor-Related Complications. Case Reports in Oncology, 2010, 3, 282-286.	0.7	4
165	A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2016, 77, 1253-1262.	2.3	4
166	Histopathological factors affecting the extraction of high quality genomic DNA from tissue sections for next-generation sequencing. Biomedical Reports, 2019, 11, 171-180.	2.0	4
167	Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG6210G). Targeted Oncology, 2020, 15, 623-633.	3.6	4
168	Protocol for a single-arm confirmatory trial of adjuvant chemoradiation for patients with high-risk rectal submucosal invasive cancer after local resection: Japan Clinical Oncology Group Study JCOG1612 (RESCUE study). BMJ Open, 2020, 10, e034947.	1.9	4
169	Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial. Gastric Cancer, 2021, 24, 467-476.	5.3	4
170	Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110091.	3.2	4
171	Efficacy of docetaxel in patients with paclitaxel-resistant advanced gastric cancer. Japanese Journal of Cancer and Chemotherapy, 2012, 39, 1511-5.	0.2	4
172	Phase II Study of Combination Chemotherapy with Biweekly Cetuximab and Irinotecan for Pre-treated Metastatic Colorectal Cancer Harboring Wild-type KRAS. Japanese Journal of Clinical Oncology, 2010, 40, 699-701.	1.3	3
173	A Case of Advanced Gastric Cancer with Poor Performance Status Which Improved by Chemotherapy. Case Reports in Oncology, 2010, 3, 262-267.	0.7	3
174	Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience. Investigational New Drugs, 2015, 33, 664-670.	2.6	3
175	Short-term safety of adjuvant chemoradiotherapy after local resection for patients with high-risk submucosal invasive rectal cancer: a single-arm, multicenter phase II trial. Japanese Journal of Clinical Oncology, 2021, 51, 707-712.	1.3	2
176	Clinical implications of using both fluoropyrimidine and paclitaxel in patients with severe peritoneal metastasis of gastric cancer: A post hoc study of JCOG1108/WJOG7312G. Cancer Medicine, 2021, 10, 7673-7682.	2.8	2
177	Cetuximab for patients with colon cancer and hepatic metastasis complicated by liver dysfunction and icterus. Gastrointestinal Cancer Research: GCR, 2009, 3, 171-2.	0.7	2
178	FOLFOX plus cetuximab for a patient with metastatic colorectal cancer with icterus due to multiple liver metastases. Japanese Journal of Cancer and Chemotherapy, 2011, 38, 1205-8.	0.2	2
179	Characteristics and clinical outcomes of patients with advanced gastric or gastroesophageal cancer treated in and out of randomized clinical trials of first-line immune checkpoint inhibitors. International Journal of Clinical Oncology, 2022, 27, 1413-1420.	2.2	2
180	Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration. Cancer Research Communications, 2022, 2, 739-753.	1.7	2

#	ARTICLE	IF	CITATIONS
181	Pathological complete response of colorectal liver metastases following chemotherapy with S-1 and oxaliplatin (SOX) in combination with bevacizumab: A case report. <i>Oncology Letters</i> , 2011, 2, 201-205.	1.8	1
182	KEYNOTE-061: pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer. <i>Annals of Oncology</i> , 2018, 29, vii49.	1.2	1
183	Clinical impact of renal impairment on the safety and efficacy of S-1 plus oxaliplatin in patients with advanced gastric cancer: a single institutional study. <i>Japanese Journal of Clinical Oncology</i> , 2019, 50, 129-137.	1.3	1
184	Safety of pembrolizumab in recurrent or advanced gastric cancer expressing PD-L1 refractory to platinum and fluoropyrimidine. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1063-1068.	2.4	1
185	A Phase 2 Study of Futibatinib (TAS-120) in Patients with Myeloid or Lymphoid Neoplasms Harboring Fibroblast Growth Factor Receptor (FGFR) 1 Rearrangements. <i>Blood</i> , 2021, 138, 3656-3656.	1.4	1
186	A case of suspected vasospastic angina related to S-1 administration. <i>Japanese Journal of Cancer and Chemotherapy</i> , 2007, 34, 1705-8.	0.2	1
187	Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 3686-3694.	7.0	1
188	Phase I study of roniciclib (BAY1000394), an oral CDK inhibitor in Japanese patients with advanced solid tumors. <i>Annals of Oncology</i> , 2016, 27, vii87-vii88.	1.2	0
189	Risk assessment based on the Risk Index for Serious Adverse Events (SAEs) in Phase I trials. <i>Annals of Oncology</i> , 2017, 28, ix108.	1.2	0
190	Tuberculous Meningitis during Chemotherapy for Advanced Gastric Cancer. <i>Case Reports in Oncology</i> , 2018, 11, 228-233.	0.7	0
191	A phase II study of nab-PTX in combination with RAM in patients with pre-treated AGC: results of final analysis. <i>Annals of Oncology</i> , 2018, 29, vii67.	1.2	0
192	The results of Japanese subgroup analyses from TAGS: a phase 3 study of FTD/TPI (TAS-102) in heavily pretreated mGC. <i>Annals of Oncology</i> , 2019, 30, vi89.	1.2	0
193	Reply to: "Multimodal Treatment of Locally Advanced Gastric Cancer: Will the West Meet the East?", by Marino, Elisabetta et al.. <i>Annals of Surgical Oncology</i> , 2019, 26, 919-920.	1.5	0
194	Was the unexpected result a response to reintroduction of effective chemotherapy?. <i>Gastrointestinal Cancer Research: GCR</i> , 2009, 3, 217-8.	0.7	0
195	Trastuzumab for a patient with heavily pretreated gastric cancer plus massive ascites and ovarian metastasis. <i>Gastrointestinal Cancer Research: GCR</i> , 2012, 5, 97-9.	0.7	0
196	Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer. <i>Japanese Journal of Cancer and Chemotherapy</i> , 2007, 34, 1079-84.	0.2	0
197	A case of advanced breast cancer associated with development of liver atrophy with progressive liver failure during treatment. <i>Japanese Journal of Cancer and Chemotherapy</i> , 2008, 35, 983-6.	0.2	0